ProMedica is participating in a research into the development of a new treatment for Benign Prostatic Hyperplasia (BPH) or enlarged prostate.

“Clinical trials are essential to the development of new medical technologies in order to achieve significant advancements in patient care,” Dr. Schuster said. “We are pleased to be a part of this pilot study, which is an important first step for histotripsy BPH treatment.”
More than 50% of men over the age of 50 and 80% of men 80 or older are affected by BPH. Traditional treatments for BPH include medications and standard and minimally invasive surgeries.
The Vortx RX is an investigational device and is limited by law to investigational use by qualified investigators in the U.S. and Canada.
Source-Newswise
MEDINDIA




Email

![Prostate Specific Antigen [PSA] Prostate Specific Antigen [PSA]](https://www.medindia.net/images/common/patientinfo/120_100/prostate-specific-antigen.jpg)




